medigraphic.com
ISSN 1561-3119 (Electronic)

2015, Number 3

<< Back Next >>

Rev Cubana Pediatr 2015; 87 (3)

Use of Surfacen in newborns with respiratory distress

López ACA, Alfonso DA, Durán MR, Villegas CD

Language: Spanish
References: 30
Page: 295-307
PDF size: 154.33 Kb.


ABSTRACT

Introduction: during the last decade, several research studies have devoted to determine the advantages of the prophylactic use of exogenous surfactant over the rescue therapeutic effect of the drug. Cuba has developed a heterologous natural surfactant of swine origin called Surfacen.
Objectives: to evaluate the use of Surfacen in newborns with respiratory distress syndrome and to identify the association of the time of drug administration with the duration of mechanical ventilation and the patient's condition on discharge from hospital.
Methods: a cross-sectional study of newborns who were admitted to the neonatology service of “Dr. Enrique Cabrera” general university hospital conducted from January 2009 to December 2011. The universe of study was 86 newborns, 87 % of whom were under 33 weeks of age and had received Surfacen. It was also given to 92.2 % of neonates weighing 750 g to 1 500 g and to 86.8 % with respiratory acidosis. In the study group, 70.9 % of patients had respiratory distress syndrome as initial diagnosis whereas on discharge, the newborns with some neonatal infection accounted for the highest percentage.
Conclusions: there was a significant statistical association between the time of Surfacen administration and the duration of the mechanical ventilation, as well as the Surfacen administration two hours after birth and the death of the patient.


REFERENCES

  1. Szallasi A, Gronowski AM, Eby CS. Lamellar body count in amniotic fluid: A comparative study of four different hematology analyzers. Clin Chemistry. 2003;49:994-7.

  2. Bengue A. Control of respiration in newborn. Clin Perinatol. 1978;5:219-21.

  3. Cloherty JP, Satrk AR. Respiratory disorders: Manual of neonatal care. 3rd ed. Boston: Little Brown and Co.; 1991. p. 527-9.

  4. Bhakoo ON, Narang A, Kumar P. Spectrum of respiratory distress in very low birth weight neonates. Indian J Pediatr. 2006;67:803-962.

  5. Chaudari R, Deodhar J, Kadam S. Gastric aspirate test for diagnosis of surfactant deficiency in neonates with respiratory distress. Ann Trop Med. 2005;25(3):205-9.

  6. Serrano AG, Ryan M, Weaver TE. Critical structure-function determinants with in the N-terminal region of pulmonary surfactant protein SP-B. Biophys J. 2006;90:238-49.

  7. Sánchez M, Martinez O, Herrera N, Ortega J. Estudio controlado del tratamiento de la enfermedad de membrana hialina del recién pretérmino con surfactante pulmonar exógeno (porcino vs. bovino). Gac Med Mex. 2005;141(4):267-71.

  8. Manzanares D, Fernández R, Moreno O, Torres O, Colomé H. Surfacen: un surfactante natural para el síndrome de distress respiratorio neonatal. Rev Cubana Pediatr. 1997;69(1):3-10.

  9. Acosta R, Arronte J, Cabrera N. Evaluación del Surfacen en el síndrome de dificultad respiratoria del prematuro. Rev Cubana Pediatr. 2000;72(4):287-94.

  10. Morilla A, Tamayo VI, Carro E, Fernández LS. Enfermedad de la membrana hialina en Cuba. Rev Cubana Pediatr [serie en internet]. 2007 [citado 22 de agosto de 2014];79(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75312007000200008&lng=es&nrm=iso&tlng=es

  11. Moreno O. Surfactante y enfermedad de la membrana hialina. Rev Cubana Pediatr [serie en Internet]. 2008 [citado 8 de marzo de 2012];80(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75312008000200015&lng=es&nrm=iso&tlng=es

  12. Bae CW, Won-Ho H. Surfactant therapy for neonatal respiratory distress syndrome: A review of Korean experiences over 17 years. J Korean Med Sci. 2009;24:1110-8.

  13. Cordero GG. Tendencias actuales en el manejo del síndrome de dificultad respiratoria en el Instituto Nacional de Perinatología. Rev Perinatol. 2006;21:2-7.

  14. García Y, Fernández RM, Rodríguez M, Pérez E. Supervivencia en el recién nacido ventilado. Rev Cubana Pediatr [serie en Internet]. 2006 Dic [citado 8 de marzo de 2013);78(4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034- 75312006000400002&lng=es&nrm=iso&tlng=es

  15. Castro López FW, Labarrere Cruz Y, González Hernández G, Barrios Acosta Y. Factores de riesgo del síndrome de dificultad respiratoria de origen pulmonar en el recién nacido. Rev Cubana Enfermer [serie en Internet]. 2007 Sept [citado 18 de agosto de 2014];23(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864- 03192007000300005&lng=es&nrm=iso&tlng=es

  16. Barría R, Pino P, Becerra C. Mortalidad en prematuros tratados con surfactante exógeno. Rev Chil Pediatr. 2008;79:36-44.

  17. Alkan S, Ozer EA, Ilhan O, Sutcuoglu S, Tatli M. Surfactant treatment for neonatal respiratory disorders other than respiratory distress syndrome. J Matern Fetal Neonatol Med. 2015;28(2):131-3.

  18. Kim SM, Park YJ, Chung SH, Choi YS, Kim CH, Bae CW. Early prophylactic versus late selective use of surfactant for respiratory distress syndrome in very preterm trials in Korea. J Korean Med Sci. 2014;29:1126-31.

  19. Flor de Lima F, Rocha G, Guimaraes H. Impact of changes in perinatal care on neonatal respiratory outcome and survival of preterm newborns: an overview of 15 years. Crit Care Res Pract. 2012;64:32-46.

  20. Dani C, Ravasio R, Fioravanti L, Circelli M. Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: Early treatment compared to late treatment. Ital J Pediatr. 2014;40:40.

  21. Jobe AH. Mechanisms to explain surfactant responses. Biol Neonate. 2006;89:298-302.

  22. Stoll B. La E. coli es la máxima causante de la sepsis precoz en lactante. New Engl J Med. 2002;347:233-9.

  23. De Sarasqueta P. Las evidencias y los estudios controlados en neonatología. Arch Argent Pediatr [serie en Internet]. 2004 [citado 17 de agosto de 2014];102(2). Disponible en: http://www.sap.org.ar/staticfiles/archivos/2004/arch04.2/%2520A2.137-144

  24. González DC, Omaña MF. Protocolos de Neonatología: Síndrome de distrés respiratorio neonatal o enfermedad de membrana hialina. Bol Pediatr. 2006;46(supl 1):160-5.

  25. Vitali F, Galletti S, Aceti A, Aquilano G, Fabi M, Balducci A, et al. Pilot observational study on haemodynamic changes after surfactant administration in preterm newborns with respiratory distress syndrome. Ital J Pediatr. 2014 mar 5;40(1):26.

  26. Bae CW. Trends in survival rate for very low birth weight infants and extremely low birth weight infants in Korea, 1967-2007. Korean J Pediatr. 2008;51:237-42.

  27. Tagare A, Chaudhari S, Kadam S, Vaidya U, Pandit A, Sayyad MG. Mortality and morbidity in extremely low birth weight (ELBW) infants in a neonatal intensive care unit. Indian J Pediatr. 2013;Jan;80(1):16-20.

  28. More K, Sakhuja P, Shah PS. Minimally invasive surfactant administration in preterm infants: A meta-narrative review. JAMA Pediatr. 2014;168(10):901-8.

  29. Aguar M, Cernada M, Brugada M, Gimeno A, Gutierrez A, Vento M. Minimally invasive surfactant therapy with a gastric tube is as effective as the intubation, surfactant, and extubation technique in preterms babies. Acta Paediatr. 2014;103:e229-33.

  30. Krajewski P, Chudzik A, Strzalko-Gloskowska B, Gorska M, Kmiecik M, Wieckowska K, et al. Surfactant administration without intubation in preterms infants with respiratory distress syndrome: Our experiences. J Matern Fetal Neonatol Med. 2014;14:1-4.




2020     |     www.medigraphic.com